These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 39266624)
1. Andrographolide sensitizes glioma to temozolomide by inhibiting DKK1 expression. Zhang ZS; Gao ZX; He JJ; Ma C; Tao HT; Zhu FY; Cheng YN; Xie CQ; Li JQ; Liu ZZ; Hou LL; Sun H; Xie SQ; Fang D Br J Cancer; 2024 Nov; 131(8):1387-1398. PubMed ID: 39266624 [TBL] [Abstract][Full Text] [Related]
2. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway. Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346 [No Abstract] [Full Text] [Related]
3. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis. Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105 [TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
5. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma. Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873 [No Abstract] [Full Text] [Related]
6. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma. Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553 [TBL] [Abstract][Full Text] [Related]
7. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway. Li C; Feng S; Chen L Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913 [TBL] [Abstract][Full Text] [Related]
8. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway. Hu YH; Jiao BH; Wang CY; Wu JL CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245 [TBL] [Abstract][Full Text] [Related]
9. miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM). He Z; Cheng M; Hu J; Liu L; Liu P; Chen L; Cao D; Tang J J Transl Med; 2022 Oct; 20(1):443. PubMed ID: 36183123 [TBL] [Abstract][Full Text] [Related]
10. Hsa_circ_0110757 upregulates ITGA1 to facilitate temozolomide resistance in glioma by suppressing hsa-miR-1298-5p. Li H; Liu Q; Chen Z; Wu M; Zhang C; Su J; Li Y; Zhang C Cell Death Dis; 2021 Mar; 12(3):252. PubMed ID: 33674567 [TBL] [Abstract][Full Text] [Related]
11. UBE2C enhances temozolomide resistance by regulating the expression of p53 to induce aerobic glycolysis in glioma. Zhou K; Wang D; Du X; Feng X; Zhu X; Wang C Acta Biochim Biophys Sin (Shanghai); 2024 Jun; 56(6):916-926. PubMed ID: 38634120 [TBL] [Abstract][Full Text] [Related]
12. Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction. Li XQ; Ouyang ZG; Zhang SH; Liu H; Shang Y; Li Y; Zhen YS J Neurooncol; 2014 Aug; 119(1):91-100. PubMed ID: 24842385 [TBL] [Abstract][Full Text] [Related]
13. DMC is not better than TMZ on intracranial anti-glioma effects. Shi L; Sun G J Cell Biochem; 2018 Jul; 119(7):6057-6064. PubMed ID: 29575236 [TBL] [Abstract][Full Text] [Related]
14. MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway. Kong S; Cao Y; Li X; Li Z; Xin Y; Meng Y J Cell Mol Med; 2020 Apr; 24(8):4677-4686. PubMed ID: 32181582 [TBL] [Abstract][Full Text] [Related]
15. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis. Deng Y; Zhu H; Xiao L; Liu C; Meng X Aging (Albany NY); 2020 Dec; 13(2):2198-2211. PubMed ID: 33316781 [TBL] [Abstract][Full Text] [Related]
16. Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294. Hua L; Huang L; Zhang X; Feng H J Biosci; 2020; 45():. PubMed ID: 32975228 [TBL] [Abstract][Full Text] [Related]
17. Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway. Yang HC; Wang JY; Bu XY; Yang B; Wang BQ; Hu S; Yan ZY; Gao YS; Han SY; Qu MQ J Cell Physiol; 2019 May; 234(5):6783-6800. PubMed ID: 30317578 [TBL] [Abstract][Full Text] [Related]
18. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways. Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789 [TBL] [Abstract][Full Text] [Related]
19. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
20. Oroxylin A reversed Fibronectin-induced glioma insensitivity to Temozolomide by suppressing IP Ding Y; Zhou Y; Li Z; Zhang H; Yang Y; Qin H; Xu Q; Zhao L Life Sci; 2020 Nov; 260():118411. PubMed ID: 32918978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]